Related Experiment Video
Updated: May 14, 2026

Assay Development for High-Throughput Drug Screening Against Mycobacteria
Published on: October 25, 2024
Baloxavir Exhibits Antibacterial Activity Against Staphylococcus aureus by Inhibiting De Novo Purine Biosynthesis
Xue Li1,2,3, Yan Yang4, Penghe Wang1,2
1Beijing Key Laboratory of Technology and Application for Anti-Infective New Drugs Research and Development, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.
Abstract:
Staphylococcus aureus remains a leading cause of morbidity and mortality worldwide, with persistent and relapsing infections posing a major global health threat. Here, we report that baloxavir, an FDA-approved influenza antiviral, exhibits antibacterial activity against S. aureus. Baloxavir demonstrated potent activity against both MSSA and MRSA clinical isolates with MICs of 2-4 μg/mL and exhibited concentration-dependent antibacterial activity in time-kill assays. Notably, baloxavir effectively eliminated intracellular S. aureus in both A549 alveolar epithelial cells and RAW264.7 macrophages at 10 μg/mL and achieved complete eradication in A549 cells at 50 μg/mL. In vivo, baloxavir (20-40 mg/kg) significantly improved survival in MRSA-infected mice from 12.5% to 75-87.5%. Transcriptomic analysis revealed significant downregulation of purine de novo biosynthesis genes, including purF and purK, which was validated by RT-qPCR (r = 0.862, p = 0.027). This study demonstrates for the first time that baloxavir possesses significant antibacterial activity against S. aureus including MRSA, positioning it as a promising repurposed candidate for treating persistent intracellular infections and post-viral superinfections.
Insights
The influenza antiviral baloxavir shows potent antibacterial activity against Staphylococcus aureus, including MRSA. This repurposed drug effectively treats persistent intracellular infections and improves survival rates in mouse models.
Area of Science:
- Microbiology
- Infectious Diseases
- Drug Repurposing
Background:
- Staphylococcus aureus (S. aureus) is a major global health concern, causing significant morbidity and mortality.
- Persistent and relapsing S. aureus infections present a substantial challenge.
- There is a need for novel therapeutic strategies against antibiotic-resistant strains like MRSA.
Purpose of the Study:
- To investigate the antibacterial activity of baloxavir, an influenza antiviral, against S. aureus.
- To evaluate baloxavir's efficacy in treating intracellular S. aureus infections.
- To explore the potential of baloxavir as a repurposed drug for S. aureus infections.
Main Methods:
- In vitro susceptibility testing (MICs) and time-kill assays against MSSA and MRSA.
- Intracellular S. aureus killing assays in A549 epithelial cells and RAW264.7 macrophages.
- In vivo efficacy studies in a mouse model of MRSA infection.
- Transcriptomic analysis to identify molecular mechanisms of action.
Main Results:
- Baloxavir demonstrated potent activity against MSSA and MRSA (MICs 2-4 μg/mL).
- Concentration-dependent killing of S. aureus was observed in time-kill assays.
- Baloxavir effectively reduced intracellular S. aureus in cell lines and improved survival in a mouse model.
- Downregulation of purine de novo biosynthesis genes (purF, purK) was identified as a key mechanism.
Conclusions:
- Baloxavir exhibits significant antibacterial activity against S. aureus, including MRSA.
- The drug is effective against intracellular S. aureus and shows promise in vivo.
- Baloxavir represents a potential repurposed therapeutic candidate for persistent S. aureus infections.
- The mechanism involves the downregulation of purine biosynthesis pathways.
Related Concept Videos
Inhibitors of Bacterial DNA Synthesis
Inhibitors of Bacterial Protein Synthesis
Inhibitors of Viral Protein Synthesis
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Inhibitors of Gram-positive Cell Wall Synthesis
Gene Regulation in Microbial Communities: Quorum Sensing
